<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03996278</url>
  </required_header>
  <id_info>
    <org_study_id>29BRC19.0018</org_study_id>
    <nct_id>NCT03996278</nct_id>
  </id_info>
  <brief_title>Comparison Thymoglobulin® and Grafalon®</brief_title>
  <acronym>THYGRET</acronym>
  <official_title>Comparison Thymoglobulin® Versus Grafalon® in Renal Transplantation - Spiesser Group (Retro/Prospective Study) I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, observational, non -interventional study with comparison
      with an historical cohort Investigators will compare the efficacy and safety of Thymoglobulin
      (Sanofi-Aventis) versus Grafalon (Neovii, previously ATG-Fresenius) in renal transplantation
      by evaluating patient survival, graft survival, delayed graft function, acute rejection, DSA
      occurrence and toxicities, various infections including CMV and BK virus incidence, MACE
      (major cardiac adverse event) and cancer.

      Investigators will also compare cumulative treatment and follow up costs and other key
      criteria available in the ASTRE database.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, observational, non -interventional study with comparison
      with an historical cohort Investigators will compare the efficacy and safety of Thymoglobulin
      (Sanofi-Aventis) versus Grafalon (Neovii, previously ATG-Fresenius) in renal transplantation
      by evaluating patient survival, graft survival, delayed graft function, acute rejection, DSA
      occurrence and toxicities, various infections including CMV and BK virus incidence, MACE
      (major cardiac adverse event) and cancer.

      Investigators will also compare cumulative treatment and follow up costs and other key
      criteria available in the ASTRE database.

      Justification for a non-interventional study: in the study the medicinal products will be
      prescribed in the usual manner in accordance with the terms of the marketing authorisation.
      The assignment of the patient to the product is not decided in advance by a trial protocol
      but falls within current practice of the centre and the prescription of the medicine is
      clearly separated from the decision to include the patient in the study. No additional
      diagnostic or monitoring procedures are applied to the patients and epidemiological methods
      are used for the analysis of collected data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2019</start_date>
  <completion_date type="Anticipated">November 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 22, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison adverse events of the 2 ATGs and data collected thanks to the ASTRE database</measure>
    <time_frame>During one year</time_frame>
    <description>All events: Death, graft loss, acute rejection, DGF, de novo DSA Severe infection (SAE), hematological adverse event (SAE), CMV infection, BK virus infection, MACE(major cardiac adverse event) and cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recipient Efficacy (any adverse events)</measure>
    <time_frame>During one year</time_frame>
    <description>comparison during the first year between the two groups for: patient and graft survival, delayed graft function, one year rate of acute rejection, occurrence od de novo DSA, renal function at one year (eGFR,MDRD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recipient Safety (any adverse events)</measure>
    <time_frame>During one year</time_frame>
    <description>Comparison during the first year between the two groups for various infections (virus, bacteria, fungi), hematological adverse event (SAE or not)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reconstitution of the T, and B cell populations</measure>
    <time_frame>During one year</time_frame>
    <description>Reconstitution of the T, and B cell populations at D0, D7, M3, M12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost comparison</measure>
    <time_frame>During one year</time_frame>
    <description>Hospitals costs at 1 year months (including re-hospitalisation costs)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>Patients in the Grafalon group</arm_group_label>
    <description>Patients in the Grafalon group (n=150) will be followed prospectively and data prospectively collected thanks to the Astre database</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients in the Thymoglobulin group</arm_group_label>
    <description>Patients in the thymoglobulin group (n=150) will be selected and analyzed retrospectively from the Astre database</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Grafalon</intervention_name>
    <description>None interventional study but there are two groups</description>
    <arm_group_label>Patients in the Grafalon group</arm_group_label>
    <arm_group_label>Patients in the Thymoglobulin group</arm_group_label>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have received or are receiving induction ATGs at the time of transplantation
        and whose data are collected from the ASTRE base in the 13 renal transplant centrers
        participating in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For the Grafalon prospective group: all first 11-12 patients from the 13 transplant
             centres receiving Grafalon according to the local practice

          -  For the Thymoglobulin group: a group of 130 patients matched for:

        age (donor and recipient) gender indication (immunological indication versus DFG) CMV
        status

        Exclusion Criteria:

          -  Patient younger than 18 years old

          -  Living donor

          -  Donor after cardiac death (because the Maastricht 3 donors are authorized recently in
             France)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yannick LE MEUR</last_name>
    <phone>298-347-074</phone>
    <email>yannick.lemeur@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christelle RATAJCZAK</last_name>
    <phone>298-347-061</phone>
    <email>christelle.ratajczak@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens Picardie, Hopital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre-François Westeel</last_name>
      <email>westeel.pierre-françois@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agnès Duveau</last_name>
      <email>agnes.duveau@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yannick Le Meur</last_name>
      <email>yannick.lemeur@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Hopital Clemenceau</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Bouvier</last_name>
      <email>bouvier-n@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Hopital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Elisabeth Heng</last_name>
      <email>aheng@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren 2</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Philippe Rerolle</last_name>
      <email>jean-philippe.rerolle@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Necker Enfant Malade</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dany Anglicheau</last_name>
      <email>dany.anglicheau@nck.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU La Milétrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine Thierry</last_name>
      <email>a.thierry@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Hopital Maison Blanche</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charlotte Colosio</last_name>
      <email>ccolosio@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Léonard Golbin</last_name>
      <email>leonard.golbin@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Hopital de Bois Guillaume</name>
      <address>
        <city>Rouen</city>
        <zip>76230</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle Etienne</last_name>
      <email>isabelle.etienne@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Strasbourg - Hopital civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie Caillard</last_name>
      <email>sophie.caillard@chu-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Buchler</last_name>
      <email>buchler@med.univ-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 28, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2019</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>THYMOGLOBULINE®</keyword>
  <keyword>GRAFALON®</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

